1. Generics Bulletin
  2. >>Products
  3. >>Biosimilars

Teva Debuts US Rituximab At A 10% Discount

Truxima Biosimilar Rival To Rituxan Is Licensed From Celltrion

 
• By Dave Wallace

Teva and Celltrion have launched the first biosimilar rituximab in the US, introducing Truxima at a 10% discount to Roche’s Rituxan.

10_Per_Cent
Teva has launched the Truxima rituximab biosimilar at a 10% discount to Rituxan • Source: Shutterstock

Teva has launched the first biosimilar rival to Roche’s Rituxan (rituximab) in the US in the form of partner Celltrion’s Truxima (rituximab-abbs), stealing a march on competitor Pfizer, the only other firm to currently hold a US approval for biosimilar rituximab.

Noting that Truxima had been introduced at a 10% discount to the originator’s wholesale acquisition cost – with the biosimilar having a WAC of $845.55 for a 100mg vial and $4,227

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products

After Jazz, Hikma Agrees $50m Settlement For ‘Most’ Xyrem ‘Pay-For-Delay’ Claims

 
• By Dean Rudge

Hikma said it would admit no wrongdoing or liability after reaching a preliminary settlement agreement over illicit ‘pay-for-delay’ claims involving its US version of Xyrem “that protects the company’s interests and provides clarity to our stakeholders.”

CIOMS Welcomes Draft Report Feedback On The Inevitable Future Of AI In Pharmacovigilance

 
• By Urtė Fultinavičiūtė

Pharmacovigilance is a perfect rule-based and manual work-intensive playground for experimenting with AI. While some off-patent drug firms are already exploring new automation tools, regulation is lagging behind, leaving a gap for uncertainty.

Viatris Pens Aprepitant Settlement Agreement After Kabi Loses Initial Patent Case

 
• By Dean Rudge

Viatris will look to introduce generic versions of Heron Therapeutics’ aprepitant brands, Cinvanti and Aponvie, around three years before patent expiry after settling litigation with the originator. Other court cases remain ongoing.